Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
21.52
-1.24 (-5.45%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Nuvectis Pharma Employees
Nuvectis Pharma had 12 employees as of March 31, 2026. The number of employees decreased by 1 or -7.69% compared to the same quarter last year.
Employees
12
Change
-1
Growth
-7.69%
Revenue / Employee
n/a
Profits / Employee
-$2,465,750
Market Cap
678.43M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 12 | -1 | -7.69% |
| Dec 31, 2025 | 13 | 0 | - |
| Sep 30, 2025 | 13 | 0 | - |
| Jun 30, 2025 | 13 | 0 | - |
| Mar 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Sep 30, 2024 | 13 | 0 | - |
| Jun 30, 2024 | 13 | - | - |
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Pharming Group | 407 |
| Phathom Pharmaceuticals | 371 |
| Rigel Pharmaceuticals | 174 |
| Allogene Therapeutics | 152 |
| Neurogene | 131 |
| BridgeBio Oncology Therapeutics | 106 |
| CytomX Therapeutics | 69 |
NVCT News
- 9 days ago - Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - GlobeNewsWire
- 9 days ago - Nuvectis Pharma receives marketing approval in China for ciprocopan - TheFly
- 9 days ago - Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors - GlobeNewsWire
- 18 days ago - StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data - Newsfile Corp
- 27 days ago - Nuvectis Pharma price target raised to $33 from $20 at Roth Capital - TheFly
- 4 weeks ago - Nuvectis Pharma 5M share Spot Secondary priced at $20.00 - TheFly
- 4 weeks ago - Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00 - TheFly